| Dr Arshin Sheybani, MD | |
|
1221 Pleasant St, Suite A100, Des Moines, IA 50309-1423 | |
| (515) 241-4330 | |
| (515) 241-4363 |
| Full Name | Dr Arshin Sheybani |
|---|---|
| Gender | Female |
| Speciality | Radiation Oncology |
| Experience | 15 Years |
| Location | 1221 Pleasant St, Des Moines, Iowa |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407082712 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Unitypoint Health - Des Moines Iowa Methodist Medi | Des moines, IA | Hospital |
| Mercyone Des Moines Medical Center | Des moines, IA | Hospital |
| Pella Regional Health Center | Pella, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Central Iowa Hospital Corporation | 1052229275 | 159 |
News Archive
Small RNA-based nucleic acid drugs represent a promising new class of therapeutic agents for silencing abnormal or overactive disease-causing genes, and researchers have discovered new mechanisms by which RNA drugs can control gene activity.
Scientists have demonstrated that a human protein known as valosin containing protein (VCP) is essential for replication of human cytomegalovirus. The findings, published in PLOS Pathogens, identify VCP as a potential new treatment target.
Bristol-Myers Squibb Company and Pfizer today announced that the companies have agreed to stop the Phase 3 AVERROES clinical trial of apixaban in patients with atrial fibrillation. The study will be stopped early because a predefined interim analysis by the independent Data Monitoring Committee (DMC) revealed clear evidence of a clinically important reduction in stroke and systemic embolism in patients with atrial fibrillation considered intolerant of or unsuitable for vitamin K antagonist therapy who received apixaban as compared to aspirin.
Reverse Medical Corporation announced today they have initiated human use of their ReStore™ Microcatheter for reestablishing blood flow in the Neurovasculature. The device was successfully used in an acute ischemic stroke patient in Germany.
A new study led by researchers at University Hospitals Coventry and Warwickshire (UHCW) NHS Trust and the University of Warwick has recommended an alternative method of pain relief for patients undergoing knee replacement surgery.
› Verified 5 days ago
| Entity Name | Central Iowa Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104879576 PECOS PAC ID: 1052229275 Enrollment ID: O20040128001102 |
News Archive
Small RNA-based nucleic acid drugs represent a promising new class of therapeutic agents for silencing abnormal or overactive disease-causing genes, and researchers have discovered new mechanisms by which RNA drugs can control gene activity.
Scientists have demonstrated that a human protein known as valosin containing protein (VCP) is essential for replication of human cytomegalovirus. The findings, published in PLOS Pathogens, identify VCP as a potential new treatment target.
Bristol-Myers Squibb Company and Pfizer today announced that the companies have agreed to stop the Phase 3 AVERROES clinical trial of apixaban in patients with atrial fibrillation. The study will be stopped early because a predefined interim analysis by the independent Data Monitoring Committee (DMC) revealed clear evidence of a clinically important reduction in stroke and systemic embolism in patients with atrial fibrillation considered intolerant of or unsuitable for vitamin K antagonist therapy who received apixaban as compared to aspirin.
Reverse Medical Corporation announced today they have initiated human use of their ReStore™ Microcatheter for reestablishing blood flow in the Neurovasculature. The device was successfully used in an acute ischemic stroke patient in Germany.
A new study led by researchers at University Hospitals Coventry and Warwickshire (UHCW) NHS Trust and the University of Warwick has recommended an alternative method of pain relief for patients undergoing knee replacement surgery.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Arshin Sheybani, MD 1221 Pleasant St, Suite A100, Des Moines, IA 50309-1423 Ph: (515) 241-4330 | Dr Arshin Sheybani, MD 1221 Pleasant St, Suite A100, Des Moines, IA 50309-1423 Ph: (515) 241-4330 |
News Archive
Small RNA-based nucleic acid drugs represent a promising new class of therapeutic agents for silencing abnormal or overactive disease-causing genes, and researchers have discovered new mechanisms by which RNA drugs can control gene activity.
Scientists have demonstrated that a human protein known as valosin containing protein (VCP) is essential for replication of human cytomegalovirus. The findings, published in PLOS Pathogens, identify VCP as a potential new treatment target.
Bristol-Myers Squibb Company and Pfizer today announced that the companies have agreed to stop the Phase 3 AVERROES clinical trial of apixaban in patients with atrial fibrillation. The study will be stopped early because a predefined interim analysis by the independent Data Monitoring Committee (DMC) revealed clear evidence of a clinically important reduction in stroke and systemic embolism in patients with atrial fibrillation considered intolerant of or unsuitable for vitamin K antagonist therapy who received apixaban as compared to aspirin.
Reverse Medical Corporation announced today they have initiated human use of their ReStore™ Microcatheter for reestablishing blood flow in the Neurovasculature. The device was successfully used in an acute ischemic stroke patient in Germany.
A new study led by researchers at University Hospitals Coventry and Warwickshire (UHCW) NHS Trust and the University of Warwick has recommended an alternative method of pain relief for patients undergoing knee replacement surgery.
› Verified 5 days ago
Dr. Mitchell R. Erickson, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1111 6th Ave, Des Moines, IA 50314 Phone: 515-643-2667 Fax: 515-643-2978 | |
Austin Peters, Radiology Medicare: Accepting Medicare Assignments Practice Location: 1200 Pleasant St, Des Moines, IA 50309 Phone: 155-460-7766 | |
Dr. Christopher J Ellerbroek, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 1221 Pleasant St, Ste 150, Des Moines, IA 50309 Phone: 515-244-5109 Fax: 515-241-3505 | |
Dr. Charles E. Zacharias, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 1111 6th Ave, Des Moines, IA 50314 Phone: 515-643-2667 Fax: 515-643-2978 | |
Dr. Mark Christopher Johnson, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1111 6th Ave, Des Moines, IA 50314 Phone: 515-643-2667 | |
Christian Kingeter, MD Radiology Medicare: Medicare Enrolled Practice Location: 1801 Hickman Rd, Des Moines, IA 50314 Phone: 515-282-8551 | |
Dr. Jon Stacy Hade, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 1221 Pleasant St, Ste 150, Des Moines, IA 50309 Phone: 515-244-5109 Fax: 515-875-9672 |